A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
CompletedNCT01853852
Amicus TherapeuticsFabry Disease
Start: 2011-09-30End: 2011-12-31Updated: 2013-12-18